Want to see HK:2138 full AI Analyst Report?
2138 Stock Chart & Stats
HK$0.57
-HK$0.01(-1.61%)
At close: 4:00 PM EST
HK$0.57
-HK$0.01(-1.61%)
Day’s Range― - ―
52-Week RangeHK$0.34 - HK$1.20
Previous CloseN/A
Volume263.00K
Average Volume (3M)629.78K
Market Cap
HK$420.75M
Enterprise ValueHK$1.22B
Total Cash (Recent Filing)HK$988.66M
Total Debt (Recent Filing)HK$1.26B
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.72%
Share Statistics
EPS (TTM)-0.34
Shares Outstanding1,185,211,300
10 Day Avg. Volume673,306
30 Day Avg. Volume629,783
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.14
P/FCF Ratio0.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)HK$5.02B
Bulls Say, Bears Say
Bulls Say
Cash Generation ResiliencyPositive operating and free cash flow (~606.6M) provide durable liquidity and operational flexibility despite accounting losses. Over the next 2–6 months this cash generation can fund working capital, service debt, and small investments without immediate equity raises, cushioning near-term recovery risks.
Diversified Consumer Healthcare ModelMulti-vertical service mix (screening, aesthetics, primary care) supports cross-referrals and recurring revenue from memberships and corporate programs. This consumer-oriented diversification reduces single-segment dependence and helps stabilize demand patterns and lifetime value across economic cycles over coming months.
Underlying Operating Profitability (EBITDA)A ~14.5% EBITDA margin indicates underlying cash profitability of core operations even as accounting items depress EBIT and net income. Sustained EBITDA supports operational scalability and provides a base to improve reported earnings if non-cash charges or one-off adjustments normalize.
Bears Say
Multi-year Revenue Decline And LossesConsecutive revenue declines and a shift from profitability to sustained losses erode earnings power and limit reinvestment capacity. Over months, weaker top-line trends hurt customer acquisition economics and increase reliance on cost cuts or external funding to restore growth and margins.
Severe Gross Margin VolatilityA collapse in gross margin suggests material mix, pricing, cost recognition, or accounting shifts, undermining earnings quality. Such volatility makes margin forecasting unreliable and raises risk that cash conversion and pricing power are impaired until business mix or cost structures are demonstrably stabilized.
Weakening Balance Sheet And Rising LeverageRising leverage alongside falling equity increases financial fragility and reduces headroom for strategic investments. Negative ROE and declining assets signal shrinking capital base; if profitability doesn't recover, elevated leverage could constrain refinancing options and raise funding costs within months.
EC Healthcare News
2138 FAQ
What was EC Healthcare’s price range in the past 12 months?
EC Healthcare lowest stock price was HK$0.34 and its highest was HK$1.20 in the past 12 months.
What is EC Healthcare’s market cap?
EC Healthcare’s market cap is HK$420.75M.
When is EC Healthcare’s upcoming earnings report date?
EC Healthcare’s upcoming earnings report date is Nov 26, 2026 which is in 116 days.
How were EC Healthcare’s earnings last quarter?
EC Healthcare released its earnings results on Jun 29, 2026. The company reported -HK$0.331 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.331.
Is EC Healthcare overvalued?
According to Wall Street analysts EC Healthcare’s price is currently Overvalued.
Does EC Healthcare pay dividends?
EC Healthcare pays a Annually dividend of HK$0.01 which represents an annual dividend yield of 1.72%. See more information on EC Healthcare dividends here
What is EC Healthcare’s EPS estimate?
EC Healthcare’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EC Healthcare have?
EC Healthcare has 1,185,211,300 shares outstanding.
What happened to EC Healthcare’s price movement after its last earnings report?
EC Healthcare reported an EPS of -HK$0.331 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.219%.
Which hedge fund is a major shareholder of EC Healthcare?
Currently, no hedge funds are holding shares in HK:2138
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EC Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.48%
Trailing 12-Months
Company Description
EC Healthcare
EC Healthcare, an investment holding firm, delivers an extensive range of medical and healthcare services throughout Hong Kong, Macau, and mainland China. Its operations are structured into three primary divisions: Medical, Aesthetic Medical and Beauty and Wellness, and an 'Others' category. The company's diverse service offerings include quasi-medical treatments, beauty and wellness programs, medical imaging, surgical procedures, aesthetic medicine, dentistry, hair restoration, vaccinations, chiropractic care, psychological support, and orthopedic services. Beyond direct patient care, EC Healthcare also provides administrative and management support, laboratory diagnostics, various marketing and performance marketing solutions, and even travel agency services. Furthermore, it retails beauty and skincare products, manages healthcare machinery, engages in property investment, offers multi-channel networking, and extends its expertise to veterinary services. Its product and service portfolio is primarily marketed under proprietary brands such as PRODERMA LAB, Swissline, Suissebeaute, and re:HEALTH. Established in 2005 and headquartered in Mong Kok, Hong Kong, the company was formerly known as Union Medical Healthcare Limited before rebranding to EC Healthcare in April 2021.
Technical Analysis
Innovative Pharmaceutical Biotech
―
Natural Beauty Bio-Technology
―
Dingdang Health Technology Group Ltd.
―
Herbs Generation Group Holdings Limited Class H
―
Eternal Beauty Holdings Limited
―